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Inhibition of Granulopoiesis in Vivo and in Vitro by [3-Lactam Antibiotics
Klaus A. Neftel, Simon P. Hauser,
and Marianne R. Muller
From the Department of Internal Medicine, University
Hospital, Zurich, Switzerland
fJ-Lactam antibiotics can induce severe neutropenia by a hitherto unknown mechanism.
Fifty cases of fJ-lactam antibiotic-induced neutropenia «1,000 neutrophils/rnrrr') from
17hospitals wereanalyzed and compared with 140 literature cases. The incidenceof neu-
tropenia was5070->15% in patients treated for ~1O days with large doses of any fJ-lactam
antibiotic but <0.1% with shorter duration of therapy. In >95% of cases recovery oc-
curred betweenone to seven days after withdrawalof fJ-Iactam antibiotics. Bone marrow
aspirates werecharacterizedby a lack of well-differentiated myeloid elements in the pres-
enceof numerousimmaturegranulocyte precursors. Ninepenicillins and eightcephalospo-
rins inhibitedin vitrogranulopoiesis in a dose-dependentmanner. Therewasa good corre-
lation between the inhibitory capacityof fJ-Iactam antibiotics invitroand the doses inducing
neutropenia in vivo. These observations may be relevant for therapy in the granulocyto-
penic patient.
Penicillins and cephalosporins (fJ-lactam antibiot-
ics) are remarkably nontoxic within a broad dose
range. Nevertheless, they induce a variety of adverse
reactions, most of which are believed to be of an al-
lergic nature [I]. Severe neutropenia is a well-known
complication of high-dose therapy with f3-lactaman-
tibiotics [2]. There are still many unanswered clini-
cal and pathogenetic questions. It is not known
whether fJ-lactam antibiotic-induced neutropenia is
a result of direct toxicity to the bone marrow or of
immune-mediated bone marrow injury. In an at-
tempt to increase our understanding of f3-lactaman-
tibiotic-induced neutropenia, we analyzed 50of our
patients with this problem, found an additional 140
literature cases, and assessed the influence of 17
selectedfJ-lactamantibiotics on in vitro granulopoiesis.
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Materials and Methods
Selection ofcases. Neutropenia was defined as
a neutrophil count of ~1,000/mm3.Criteria for as-
sessing the causal relation between neutropenia and
f3-lactam antibiotics were adapted from those of
Karch and Lasagna [3]. Neutropenia was thus in-
duced by f3-lactam antibiotics only if it followed a
reasonable time sequence from administration of the
drug, disappeared on stopping administration of the
drug, and was not explainable by the patient's clini-
cal condition.
Cases were excluded in which other drugs had to
be considered as a possible cause or in which the
cause-and-effect relation remained otherwise ques-
tionable.
Cases of f3-lactam antibiotic-induced neutropenia
came to our attention in one of the three following
ways: (1) they were encountered during a multicenter
study concerning the side effects of penicillin G [3]
and other f3-lactam antibiotics (authors' unpublished
observations); (2) they occurred from September
1980 to December 1983 in the Medical Clinic of the
University Hospital, Zurich; or (3) specimens from
such cases were sent to us for evaluation of suspected
f3-lactam antibiotic-induced reactions.
The literature cases were obtained through a com-
puter search (MEDLINE; National Library of Medi-
cine, Bethesda, Md) from 1945 to 1983.
Analysis of clinical data. The total dose of (3-
lactam antibiotic given within the course of therapy
before neutropenia developed was determined for
each patient, and the mean daily dose (MDD) was
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then calculated. In children the doses per kilogram
of body weight were translated to the same relative
doses given to a patient weighing 65 kg. Therapy
breaks of <48 hr were ignored. If more than one ~­
lactam antibiotic was involved, the drug given while
neutropenia developed was considered as the main
cause. If two ~-lactam antibiotics were given simul-
taneously, the one given in the higher total dose was
considered as the main cause.
Concomitant symptoms of neutropenia were de-
fined as follows. Eosinophilia was ~100/0 of the white
blood cell count or an absolute count of ~ 750/mm3 •
Thrombocytopenia was ~100,000 platelets/rnm",
Reticulocytopenia was ~0.25 0J0 of the red blood cell
count. Fever was a temperature ~38.0 C after at least
three afebrile days (~37.2 C) with no other cause of
fever evident.
Bone marrow cultures. Cancellous bone samples
from hematologically normal donors undergoing or-
thopedic surgery were collected in Hanks' solution.
A modification of the method of Pike and Robin-
son [4] for culture of myeloid progenitor cells was
used. Dextran-sedimented bone marrow cells were
plated at a concentration of 105 mononuclear
cells/ml of supplemented minimal essential medium
containing 0.30/0 agar and 20070 pretested fetal calf
serum. Human placenta-conditioned medium [5]
served as the source of colony-stimulating factor.
Cultures were set up in triplicate and incubated at
37 C in a humidified atmosphere plus 5070 CO 2 , Af-
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ter eight days aggregates of ~40 cells were scored as
colonies and those of three to 39 cells as clusters.
Because cluster formation always paralleled colony
formation, only the latter was considered for final
evaluation.
~-Lactam antibiotics were dissolved in 0.9070 NaCI
at 100mg/ml and further diluted with supplemented
medium. In some experiments ~-lactam antibiotics
were added after the culture process was started by
overlaying the drug in 0.1 ml of complete medium
on top of the agar culture to the final concentration
required.
Results
In vivodata. Table 1 summarizes data in 50 cases
of ~-lactam antibiotic-induced neutropenia from a
total of 17 hospitals.
Ninety-six percent of these cases were detected
only after therapy with ~-lactam antibiotics of ~1O
days. In cases in which neutrophil counts were done
daily, a decrease in count was seen over several days
until total agranulocytosis was established or ther-
apy with ~-lactam antibiotics was discontinued.
In contrast to the duration of therapy, MDDs, and
thus total doses given before neutropenia developed,
varied markedly with different ~-lactam antibiotics.
In the cases of penicillin G, floxacillin, and ceftri-
axone, with six or more cases each, these differences
were significant (table 1).
Table 1. Data from 50 cases of {3-lactam antibiotic-induced neutropenia from 17 hospitals.
No. of cases with
Mean (range) Mean ± SO dose (g)
No. of duration of Eosino-
Substance cases therapy (days) Total Daily Rash philia Fever
-_._-- _.
- -
Penicillin G 26 23 (13-34) 268 ± 97* 11.6 ± 3.5t II 10 II
Floxacillin 7 27 (21-40) 197 ± 67*:1: 7.2 ± 1.1t§ 4 2 3
Ceftriaxone 6 21 (8-25) 51 ± 29+ 2.3 ± I.O§ 0 3 2
Amoxicillin 2 13 (6-20) 216 ± 275 12.0 ± 12.0 0 0 0
Piperacillin 2 22 (17-27) 400 ± 232 17.4 ± 4.9 0 0 0
Cefotaxime 2 29 (27-31) 208 ± 101 7.0 ± 2.8 0 0 I
Apalcillin I 16 162 9.0 0 I 0
Ticarcillin I 15 516 34.4 0 I 0
Mezlocillin I 36 594 16.5 I I I
Cephalothin I 18 139 7.7 0 0 0
Cephacetrile I 36 432 12.0 1 0 I
Total 50 23.2 (6-40) 243 ± 139 10.3 ± 5.9 17 18 19
-
---- _.---_.- - ---_.-
* P < .05 by t test.
t p < .01 by t test.
:I: P < .0 I by t test.
§ P < .01 by t test.
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On discontinuation of therapy with fJ-lactam an-
tibiotics, complete recovery took place within one
to seven days.
Simultaneous eosinophilia, rash, and/or feverwere
observed in 35 (700/0) of the cases (table 1). In 19
(38%) cases one symptom was seen, in 14 (28%)
cases two symptoms were present, and in 2 (4%)
cases all three occurred together. There did not ap-
pear to be any predictable combination of these
symptoms, which disappeared within one to four
days after cessation of therapy with fJ-lactam anti-
biotics.
Thrombocytopenia was noted in nine of 36 pa-
tients for whom platelet counts were done and
reticulocytopenia in two of 19 cases.
Bone marrow findings. In 24 cases a bone mar-
row aspirate was available. Numerical values of
differential counts are not presented because bone
marrow aspiration was done at different intervals
with regard to the nadir of neutropenia.
Lack of well-differentiated myeloidelements in the
presence of still numerous granulocyte precursors
was a typical finding. The mitotic pool of
granulopoiesis was found to be normocellular or
even hypercellular; however, occasionally it was
hypocellular. Severe hypocellularity has only been
found in cases of total agranulocytosis. Such a
"maturation arrest" in aspirates taken immediately
at the termination of therapy was usually at the
promyelocyte stage, whereas ~24 hr later it was at
the myelocyte or metamyelocyte stage.
In four cases bone marrow aspirates were per-
formed at the beginning of the decrease in number
of peripheral granulocytes. In these cases myeloblasts
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and promyelocytes were still numerous; myelocytes
were greatly reduced in number or lacking, whereas
the numbers of metamyelocytes, band forms, and
segmented granulocytes were still normal.
In vitro data. Addition of various (3-lactaman-
tibiotics to normal bone marrow cultures resulted
in a dose-dependent inhibition of myeloidcolony for-
mation, as illustrated for penicillin G, cloxacillin,and
ceftizoxime in figure 1.There wereimpressive differ-
ences in absolute potency of the (3-lactamantibiot-
ics studied. However, the shape of the dose-effect
curves was alwayssimilar. Concentration of {3-lactam
antibiotics leading to 50% inhibition of colony for-
mation (ICso) wereinterpolated from the dose-effect
curves and served as a simple measure of in vitro
toxicity (table 2). Cephalosporins were from three
to 25 times more effective than semisynthetic penicil-
lins. The sensitivity of cells from different bone mar-
row donors to a particular substance varied greatly.
In some instances, especially in the low concentra-
tion range, deviations from median values exceed-
ing 50% were seen. However, the relation of inhibi-
tion of a given bone marrow sample by different
(3-lactam antibiotics remained constant.
Overnight exposure (18 hr) of bone marrow cells
to (3-lactam antibiotics in concentrations otherwise
resulting in 90%-100% inhibition, followedby wash-
ing for removal of drug, did not affect colony for-
mation. The trypan blue-exclusion test showed full
viability of cells during preincubation as compared
with controls (viability, >95%).
However, when (3-lactam antibiotics were added
after the culture process had begun, the inhibitory
effect was progressively diminished. In five culture
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Figure 1. Inhibition of colony for-
mation by ceftizoxime (0), cloxacillin
(Ll), and penicillin G (D). Data are
median values from differing numbers
of cultures (table 2).
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Table 2. ICso values of penicillin G, eightsemisynthetic
penicillins, and eight cephalosporins in vitro.
Substance
Penicillin
Mezlocillin
Ticarcillin
Piperacillin
Methicillin
Penicillin G
Oxacillin
Cloxacillin
Azlocillin
Floxacillin
Cephalosporin
Moxalactarn
Cefoxitin
Ceftriaxone
Ceftizoxime
Cephalothin
Cefazolin
Ceftazidime
Cefotaxime
Medium (range)
IC,o (ug/rnl)
550 (280->1,000)
520 (300->1,000)
470 (153->1,000)
470 (155-670)
380 (45-560)
370 (62.5-560)
340 (251-380)
320 (12-1,000)
105 «62.5-230)
35 (12-62)
32 (16-36)
30 (2-43)
20 (10-33)
16 (16-17)
15 (7-18)
12 (1-16)
7 (1-8)
No. of
cultures
4
9
5
6
15
4
4
6
6
4
3
5
4
3
3
3
4
experiments with ceftazidime we found inhibition
to be reduced by "'50070 when the drug was added
after 24 hr and by rv75% after 48hr. Addition after
~72 hr no longer induced significant inhibition.
Discussion
In vivo data. In the literature we found an addi-
tional 140 cases fulfilling the above criteria for (3-
lactam antibiotic-induced neutropenia (table 3). The
literature data largely confirmed the observations
with our 50 subjects and allowed estimation of the
incidence of (3-lactamantibiotic-induced neutrope-
nia and the risk of a relapse when the patient is
rechallenged.
Relation of neutropenia to duration and dosage
of therapy with(3-lactam antibiotics. In 91% of the
literature cases neutropenia did not occur before day
10after therapy was started. Indeed, duration of ther-
apy with (3-lactamantibiotics of at least 10 days ap-
pears to be a threshold for inducing neutropenia. In
Table 3. Data from 140 literature cases of J3-lactam antibiotic-induced neutropenia.
Mean (range) Mean ± SD dose (g)
No. of duration of
Substance cases therapy (days) Total Daily Reference
Oxacillin 22 24 (17-75) 249 ± 114 11.1 ± 4.8 6-16
Penicillin G 20 24 (10-36) 335 ± 301 14.1 ± 12 16-31
Cephalothin 18 20 (2-34) 141 ± 83 7.4 ± 2.9 II, 32-38
Nafcillin 18 18 (2-38) 169 ± 68 10.5 ± 2.8 39-48
Methicillin 9 17 (4-21) 171 ± 102 9.5 ± 3.4 49-54
Cloxacillin 8 (+ I)- 25 (17-40) 216 ± 82 9.3 ± 3.5 24, 55-57
Ampicillin 8 20 (9-32) 198 ± 125 10.9 ± 7.7 16, 23, 58-62
Carbenicillin 6 20 (15-24) 536 ± 213 25.8 ± 9.3 23, 24, 63
Cefotaxime 5 22 (9-37) 171 ± 162 6.5 ± 3.7 16, 64, 65
Piperacillin 4 24 (22-26) 373 ± 142 15.4 ± 5.9 46,66
Ticarcillin 4 15 (9-29) 246 ± 111 18.5 ± 5.5 67-69
Ceftazidime 3 14 (7-25) 66 ± 73 4.1 ± 2.3 16,70
Amoxicillin 2 21 (20-22) 74 ± 2 3.5 ± 0.3 16
Cephaloridine 2 16 (5-27) 115 ± 70 9.6 ± 4.9 71,72
Mezlocillin 2 17 (12-22) 134 ± 65 9.5 ± 7.8 73, 74
Ceftriaxone 2 6 (5-7) 30 ± 7 4.9 75
Azlocillin 1 19 223 11.7 76
Phenethicillin I 23 138 5.0 29
Cefamandole I 24 254 10.6 11
Cefuroxime 1 28 168 6.0 30
Cefoperazone I 18 108 6.0 77
Cephapirin I 6 24 4.0 78
Total 140 20.6 (2-75) 224 ± 178 10.95 ± 7.5
- The additional case was seen after 263 days of peroral therapy (1.5 g per day).
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• If exact values were lacking, these symptoms were consi-
dered present when they were at least stated qualitatively.
Table 5. Concomitant symptoms in 140literature cases
of f3-lactam antibiotic-induced neutropenia.
Exposure to the same or a different fJ-Iactam an-
tibiotic induced a relapse in only 12(31070) of the 39
patients rechallenged (including our cases) [6, 7, II,
13,26,27,29,30,32,36,40-42,46,49,52,59,63,
67, 69, 85J. The induction of a relapse depended
clearly on the duration and dosage of therapy with
(3-lactam antibiotic, as did the first induction of neu-
tropenia. This dependence was true irrespective of
the time between complete recovery from neutrope-
nia and rechallenge. There have been relapses
reported months and even years after the first epi-
sode of neutropenia [27, 29].
Relation of neutropenia to other symptoms.
Symptoms accompanying neutropenia in the litera-
ture cases were similar to those seen in our cases (ta-
ble 5).
Eosinophilia, rash, and fever combined were
reported in 10cases, two of the symptoms appeared
in 17cases, and an isolated symptom was seen in 37
cases. The three symptoms appear to represent a syn-
drome that is pathogenetically related to neutro-
penia.
Thrombocytopenia and reticulocytopenia occur-
ring along with neutropenia suggest that (3-lactam
antibiotics can inhibit all three hematopoietic cell
lines. However, when bone marrow aspirates were
analyzed no clear substrate for this inhibition could
be identified.
In vitro data. All of the (J-Iactam antibiotics
studied inhibited in vitro granulopoiesis dose depen-
dently. However, progenitor cells were not directly
killed by fJ-Iactam antibiotics. If the bone marrow
cells were incubated overnight with (3-lactamantibi-
otics followed by washing and plating, no inhibition
of colony formation was observed, and the develop-
mental potential of the cells appeared to be main-
tained. However, (J-Iactamantibiotics wereonly fully
effective during the first 24 hr of the culture pro-
Table 4. Incidence of neutropenia in four different ser-
ies of patients treated with methicillin.
Mean duration Mean total Incidence
Reference of therapy (days) dose (g) (%)
Nahata et al. [44] 6.5 45 0
Kitzing et al. [51] 10 130 0
21 273 12
Kancir et al. [85] 27 >325 12.2
patients treated with large doses of fJ-Iactamantibi-
otics for ;?;1O days, neutropenia developed with an
incidence of from 5070 to >15070 [3, 44, 48, .51, 54,
64, 66, 75, 79-84]. With shorter therapy courses,
however, the incidence can be estimated to be as low
as 0.1070.
This point can be illustrated with three articles that
studied a total of 144 patients receiving methicillin
(table 4). Yow et al. [54], in a 10 year assessment of
methicillin-associated side effects, found leukope-
nia to occur in 16 of 102 children who received 200
mg of methicillin/kg per day for ;?;1O days. In four
instances the absolute neutrophil count dropped to
<500/mm3 • In contrast, nearly 3,000 patients who
received the drug for <10 days did not develop leu-
kopenia.
Besides intrinsic myelosuppressive activity, phar-
macokinetic properties might be important for the
overall myelotoxicity of a given fJ-Iactam antibiotic.
Because ceftriaxone has an very long serum half-life,
neutropenia already occurred in a dose range lower
than with any other fJ-Iactam antibiotic. However,
this observation need not imply an increased risk be-
cause this substance reaches sufficient antibacterial
activity with lower daily doses as well. Pharmacoki-
netic factors might also account for the fact that in
the 15 literature cases in which treatment was oral
[10, 16, 29, 56, 57,61] or im [29, 33, 52, 53, 72, 78J
total doses of (3-lactamantibiotics given were lower
than when treatment was iv, although duration of
such treatment was the same.
Complete recovery within one to seven days after
discontinuation of therapy with fJ-Iactam antibiot-
ics was observed in 94070 of the well-documented
literature cases. Duration of recoveryof four or more
days was only seen in cases of total agranulocytosis.
Permanent damage of granulopoiesis was never seen.
In one case a decreased neutrophil count remained
constant [41J, and in three cases the count even
returned to normal levels during continuous ther-
apy [32, 39, 42J.
Symptom
Eosinophilia*
Rash
Fever*
Thrombocytopenia
Reticulocytopenia
No. positive/no. of
patients studied (070)
25/79 (32)
26/64 (41)
52/76 (68)
9/69 (13)
12/27 (44)
IC so
100 200 300 400 500 600 /.I9/ml
Figure 2. Correlation (r = .804; P < .01) of MODs
inducing neutropenia in vivo with ICso values in vitro:
PNG = penicillin G; Cefo = cefotaxime; Cefta =
ceftazidime; Ceftr = ceftriaxone; Ceph = cephalothin;
Clox = cloxacillin; Flue = flucloxacillin (Floxacillin);
Meth = methicillin;Mezl = mezlocillin; Oxa = oxacillin;
Pip = piperacillin; and Tic = ticarcillin.
covalent binding of carbonyl groups to amino groups
of membrane proteins or simple uptake and bind-
ing to intracellular structures are unlikely to be deci-
sive pathogenic steps.
Although the in vitro observations as a whole can-
not yet be interpreted comprehensively, they match
well the typical findings in the bone marrow aspirate
of patients with fJ-lactam antibiotic-induced neu-
tropenia. As described above, immature myeloid
precursor cells are usually numerous, whereas more
mature forms are lacking. Furthermore, bone mar-
row aspirates taken early during development of neu-
tropenia suggest that postmitotic maturation is not
affected. fJ-lactam antibiotics appear not to affect
the granulocytic stem cell itself but might exert their
inhibitory effects on other precursor cells within the
mitotic pool. Consequently, "proliferation arrest"
would describe what seems to happen better than
the generally used phrase "maturation arrest." This
particular proliferation disturbance may explain the
rapid recovery from neutropenia generally seen af-
ter withdrawal of therapy with fJ-lactam antibiotics.
Clinical consequences. In only eight (4.2070) of
the 190 cases analyzed did a secondary infection
ascribable to neutropenia develop, and it was never
fatal. There might be some bias in that cases with-
out documented recoveryon discontinuation of ther-
apy with fJ-lactam antibiotics were not considered.
There are literature cases otherwise fullfulling our
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cess. An inhibitory effect of fJ-lactam antibiotics on
in vitro granulopoiesis is thus seen only when these
drugs are present during the early proliferative phase.
Furthermore, we have noted that addition of acute-
phase serum and/or lymphocytes from two patients
with penicillinO-induced neutropenia to autologous
bone marrow cultures did not alter the effects of
fJ-lactam antibiotics [86]. These in vitro findings
taken together are consistent only with a nonim-
munologic pathogenesis of fJ-lactam antibiotic-in-
duced neutropenia, assuming that similar mecha-
nisms are operative in vivo.
Several articles have reported drug-dependent an-
tibodies to neutrophils, which could explain fJ-lactam
antibiotic-induced neutropenia by a mechanism
similar to that seen in penicillin-induced immuno-
hemolytic anemia [16, 25,87,88]. With a solid-phase
RIA we found circulating IgO antibodies to penicil-
lins in a series of patients after treatment with large
doses of penicillin 0 [2, 89] as well as ampicillin,
floxacillin, or piperacillin [90], whether the subjects
had neutropenia or not. Circulating antibodies to
penicilloylated cells may only reflect an increase in
levelof circulating antibodies to drug, which appears
to be common after very high-dose therapy with
fJ-lactam antibiotics.
Inhibitory capacity (ICso) of different fJ-lactam an-
tibiotics in bone marrow cultures correlates wellwith
the MDDs inducing neutropenia in patients (figure
2). Bone marrow cultures seem to allow for an ap-
proximate estimation of the myelotoxicitythat would
be expected in vivo. However, there are important
discrepancies between semisolid agar cultures and
the situation in vivo, mainly concerning the kinetics
and protein binding of fJ-lactam antibiotics. On the
basis of preliminary experience, webelieve that with
a liquid culture system allowing for multiple addi-
tion and removal of the drug during the culture pro-
cess, an improved test model could be built up.
The inhibitory effect of fJ-lactam antibiotics on
cell proliferation appears not to be restricted to
granulopoiesis. Some cephalosporins were found to
dose dependently inhibit lymphocyte proliferation
after stimulation with mitogens [91,92]. Preincuba-
tion with moxalactam followed by washing did not
affect viability and subsequent proliferation of cells
[92]. Similar effects were shown with penicillin 0 in
cultures of isolated rat hepatocytes [93, 94]. It re-
mains unclear how this inhibition of cell prolifera-
tion is achieved. Because the effect can be abolished
by thorough washing after preincubation, stable
MDD
9
20
15
10
;eph Flue
.Cef
5
.Cefta
.Ceftr
eTic
.Pip
PNG
•Oxe eMezl
•
Clox
.Moth
•
95
96
criteria in which death occurred from various causes
before the peripheral granulocyte count rose again
[73]. Nevertheless, the risk for important sequelae
of f3-lactam antibiotic-induced neutropenia appears
to be low.
The more important question is what conse-
quences do the myelosuppressiveeffects of high-dose
therapy with f3-lactam antibiotics have in the treat-
ment of the granulocytopenic patient, especially af-
ter cytostatic treatment? In such cases long-term
therapy with cumulative doses, often of >200 g, of
one or more f3-lactam antibiotics are given. In
hematologically normal individuals this treatment
would lead to neutropenia in 5070 to 15070 of those
treated. Currently severalstudies are being conducted
to assess whether double f3-lactam antibiotic regi-
mens can reduce toxicity of f3-lactam-aminoglyco-
side combinations without giving up double antibi-
otic coverage. Indeed, in a recent trial a double
f3-lactam antibiotic regimen resulted in lower
nephrotoxicity but also in a significantly longer du-
ration of granulocytopenia [95].
In an ongoing retrospective study we have ana-
lyzed 227 granulocytopenic episodes (granulocyte
count, <500/mm3) in patients with acute myeloge-
nous leukemia. We found that beginning therapy
with f3-lactam antibiotics simultaneously with or very
early after cytostatic treatment is associated signifi-
cantly (P < .001)with a longer duration of granulo-
cytopenia. Consequently, in patients with granulo-
cytopenia for >20 days, the mean total dose of
f3-lactam antibiotics and the mean dosage of f3-lactam
antibiotic per granulocytopenic day weredispropor-
tionately higher as compared with the remaining pa-
tients treated with f3-lactam antibiotics (authors' un-
published observations).
Duration and severity of granulocytopenia remain
the most important prognostic factors for the pa-
tient with neutropenia after cytostatic therapy for
malignant disease. It is very important to clarify
whether f3-lactam antibiotics can delay regeneration
of myelopoiesisafter cytostatic therapy and how such
an effect could be recognized.
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